Toronto scientists isolate the ‘anti-CRISPR’ to shut off uncontrollable gene editing – National Post
National Post |
Toronto scientists isolate the ‘anti-CRISPR‘ to shut off uncontrollable gene editing
National Post Discovered in the 1990s from studies on bacteria, with most progress in the last few years, CRISPR is the name for repeating bits of DNA that evolved as a kind of genetic immune system. By programming it in the lab and delivering it to a cell, CRISPR … New Software Simplifies CRISPR Methodology For Gene EditingTech Times Biotech firms form patent alliance over interference proceeding against CRISPR patent applicationIPWatchdog.com News New and More Precise CRISPR/Cas9 Techniq…Genetic Engineering & Biotechnology News GenomeWeb –StreetInsider.com –TechNewsGazette all 14 news articles » |
Prostate Cancer News Today |
Results of Phase 3 Study of Immunotherapy Prostvac Due at Year’s End
Prostate Cancer News Today Bavarian Nordic announced that full data from its Phase 3 study assessing the effectiveness of its immunotherapy candidate, Prostvac, to improve survival in people with metastatic castration-resistant prostate cancer (mCRPC) is now expected late in … |
Genetic Literacy Project |
Biotech industry focuses on CRISPR, new gene breeding techniques to break regulatory logjam
Genetic Literacy Project Commodity groups, farm organizations and others considered the summer’s GMO labeling law a prudent compromise for what had become a divisive issue. How the United States Department of Agriculture decides to lay out these new labeling rules over the … |
|
Cancers evade immunotherapy by ‘discarding the evidence’ of tumor-specific mutations
EurekAlert (press release) Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination of certain genetic … |
|
ASSASSIN’S CREED (PG-13)
Berkshire Eagle (subscription) A space ship on automatic pilot, heading on a 120-year journey toward a distant colonized planet, is the setting for a creepy courtship that evolves between two of the passengers who have sprung out of their states of suspended animation. But what … |
Community Financial News |
FDA OKs Sangamo’s IND for gene therapy candidate for hemophilia A; shares ahead 7% premarket
Seeking Alpha The FDA clears Sangamo BioSciences’ (NASDAQ:SGMO) Investigational New Drug (IND) application for gene therapy candidate SB-525 for the treatment of hemophilia A. Phase 1 development to assess safety, tolerability and potential efficacy may now … Sangamo BioSciences Announces FDA Clearance Of Investigational New Drug Application For SB-525 Gene Therapy …PR Newswire (press release) |